A key warning sign is a clinic presenting a stem cell, exosome, or other regenerative hair treatment as FDA-approved, proven, or equivalent to a routine hair transplant. No stem cell or regenerative medicine product is FDA-approved for hair loss. Before paying, ask what the treatment contains, whether it is part of a registered clinical study, and what any registration or listing actually establishes (FDA patient information on regenerative medicine therapies).

Start with the approval claim

Be cautious if advertisements use terms such as “FDA registered,” “FDA compliant,” or “FDA-cleared” without naming a specific FDA approval for the hair-loss treatment being offered. Registration of a facility is not approval of a product, and an investigational new drug application, or IND, is not an FDA marketing approval. These are different regulatory concepts; ask the clinic to explain precisely what status it is claiming and to provide documentation you can verify. (American Hair Loss Association overview of exosome status)

A clinical-trial listing also should not be confused with FDA approval or proof that a treatment works. A listing can help you identify a study, but it does not by itself show that the FDA has reviewed a product as effective or authorized its routine sale. Ask for the study title, registry identifier, sponsor, and a contact who can confirm whether the clinic is actually a study site. If those details are not provided, treat a vague “we are in a trial” claim as a reason to pause.

The distinction matters because research into cell-based approaches is ongoing, while clinical availability is not the same as established benefit. A 2023 systematic review covered 15 studies and 653 participants, but its authors noted limitations including small samples, varied protocols, and short follow-up (the review in Cells). Early research is not a guarantee that a particular clinic’s product, preparation, or treatment schedule has been tested.

Ask what you are being charged for

A price tag alone does not prove that a treatment is improper. However, if a clinic says an experimental intervention is being provided as research, ask whether you are being invited to participate in a clinical study or are purchasing a commercial service. Request a written explanation of what the fee covers, whether any part of the treatment is investigational, and what costs may arise from follow-up or complications. Do not rely on verbal assurances that payment is “required for the trial” without checking the study documents and contacting the study sponsor.

Be especially wary of sales pressure, limited-time offers, or promises of guaranteed regrowth. A responsible discussion should explain uncertainty, alternatives, potential risks, and what is not known. The FDA advises patients to discuss regenerative medicine products with a qualified health professional and to be cautious about claims that a product can treat conditions without appropriate authorization (FDA patient information). You can take time to review paperwork or seek an independent medical opinion before agreeing to treatment.

Decode the treatment name and the evidence

“Stem cell hair treatment” is not one standardized procedure. Investigational approaches include transplanting cells or micrografts, using cell-conditioned medium, and using exosomes; the materials and methods can differ. Ask the provider to identify the source of the material, how it is processed, what is injected or applied, and which published human study matches the exact product and protocol being offered. A broad label does not answer those questions.

Exosomes deserve particular care. Human evidence remains preliminary, and there is no standardized treatment protocol; the FDA has not approved exosomes for hair loss. A clinic should not imply that the word “exosome” itself demonstrates safety or effectiveness (American Hair Loss Association’s exosome information). Likewise, marketing language about “hair cloning” can overstate what is available: functional lab-grown follicles that cycle, connect with surrounding tissue, develop a blood supply, and pigment are not clinically available (review of follicle regeneration).

Compare the proposal with established options rather than assuming that a regenerative label means a transplant replacement. FUE and FUT surgery redistribute a patient’s existing follicles; they do not create new lab-grown follicles (ISHRS patient guide to hair transplant surgery). When you visit a Hair Transplant Clinic, ask for a diagnosis, a clear explanation of the proposed procedure, and realistic expectations. Hair Transplant Clinics may discuss different options, but the provider should distinguish established care from experimental or still-developing approaches.

Questions to take to a consultation

Ask: What exactly will be used, and where does it come from? Is this a clinical study or a service I am buying? If it is research, what is the study identifier, who sponsors it, and what document explains risks, fees, and follow-up? What evidence supports this exact product and protocol—not just a general category of treatment?

You can also ask what happens if there is no improvement, who manages adverse effects, and whether conventional options are appropriate for your diagnosis. A Hair Transplant Clinic should be willing to explain the limits of its evidence and give you time to consider your choices. If the answers stay vague or the claims rely mainly on testimonials, postpone payment and seek another qualified opinion.

Frequently Asked Questions

Does a registered clinic or product have FDA approval?

No. Facility registration is not the same as FDA approval of a treatment, and an IND is not permission to market a product as an approved therapy. Ask what specific approval the provider means and verify the claim through the FDA’s patient information on regenerative medicine (FDA guidance).

Is a treatment legitimate if it is listed in a clinical-trial registry?

A listing may help identify a study, but it does not establish that the treatment is FDA-approved or proven effective (FDA patient information). Confirm that the clinic is connected to the named study and review its consent materials before deciding whether to participate or pay.

Are stem cell treatments the same as a hair transplant?

No. A conventional FUE or FUT transplant moves existing follicles from one area to another, while cell-based approaches are investigational and use different materials and methods (ISHRS patient guide). Ask the clinician to explain which approach is being offered and what evidence supports it.

When a claim sounds certain but the product, study, or regulatory status is unclear, pause and ask for specifics. An informed decision starts with clear answers, realistic expectations, and time to review the evidence.

Stem cell hair treatments abroad may be offered under appealing names, but they are not established cures, and no stem cell or regenerative product is FDA-approved for hair loss. Before traveling, find out exactly what is being injected or transplanted, what evidence supports it, and who will manage complications and follow-up when you return home. A treatment marketed as “stem cell” may describe different procedures, so the label alone is not enough to judge what you are being offered.

What “stem cell hair treatment” can mean

The term can refer to several different approaches, including transplantation of cells or small tissue grafts, use of stem-cell-conditioned medium, or administration of cell-derived exosomes. These approaches are not interchangeable, and a clinic should explain the material used, how it is prepared, and how it is delivered. “Stem cell” is not a guarantee that a treatment contains living stem cells or works by creating new follicles.

Human research is developing, but the evidence remains limited. A 2023 systematic review identified 15 studies involving 653 participants and several different cell-based approaches; the authors noted limitations including small samples, varied protocols, and short follow-up (the review in Cells). Results from one method therefore cannot automatically be applied to another product or clinic’s protocol.

It is also important to distinguish regenerative injections from hair transplantation. Established FUE and FUT surgery move a patient’s existing follicles from one area of the scalp to another; there is no clinically available operation that creates new lab-grown follicles and transplants them (the ISHRS patient guide). If a provider promises “hair cloning,” ask for evidence that the specific procedure is clinically available and independently validated.

Why going abroad calls for extra checking

Travel can make it harder to verify a provider, understand consent documents, arrange follow-up, or obtain care if a problem develops after you return. These practical challenges do not mean that every overseas clinic is unsafe. They do mean that decisions should be based on transparent information—not promotional photos, discounts, or assurances that a product is “approved” without naming the regulator and the precise authorization.

The FDA says regenerative medicine therapies have not been approved for hair loss. Its patient information advises consumers to check a product’s regulatory status and warns that registration of a facility does not mean a product is approved (FDA information for patients). Approval rules differ by country, so ask for the specific authorization applicable where the treatment will occur, and verify it with the relevant national regulator. Do not treat a clinic’s facility registration, a research filing, or an “investigational” label as proof of approval.

Exosome marketing deserves particular scrutiny. The American Hair Loss Association reports that exosomes are not FDA-approved for hair loss or any other condition, that human evidence is preliminary, and that protocols are not standardized (its exosome status page). Ask whether the product is human-derived, what it contains, how it is processed and stored, and whether the provider can supply documentation you can review before paying or traveling.

A practical checklist before you book

Ask for the clinician’s full name, qualifications, and role in each step of care. Confirm who evaluates you, who performs the procedure, and who is responsible if you develop an infection, inflammation, or another complication. Request a written treatment plan that names the product and procedure—not just a brand or the phrase “regenerative therapy”—and explains realistic benefits, uncertainties, alternatives, and potential harms.

Ask for published human evidence on the exact treatment being offered, including study size, follow-up period, and whether results were measured objectively. A systematic review published in 2026 covered 20 clinical studies and 724 patients across several different regenerative approaches, illustrating how varied the treatments and evidence are; findings for one category should not be presented as proof for another (the 2026 systematic review). Ask whether the clinic’s claims match the studied product, dose, and protocol. Be cautious about guaranteed results, pressure to pay quickly, or claims that a treatment is risk-free.

Plan follow-up before departure. Get copies of your records, consent forms, product details, and aftercare instructions in a language you understand. Ask a local dermatologist or hair-loss specialist to review the proposal before you travel, and discuss how you will seek care at home if symptoms arise. Many Hair Transplant Clinics offer multiple services, but marketing a service does not establish that it is effective or approved. When evaluating a Hair Transplant Clinic, look beyond the name: verify the individual clinician, exact procedure, and arrangements for ongoing care.

Consider the diagnosis and established options

Hair loss has multiple possible causes, and the right treatment depends on identifying yours. A dermatologist can assess the pattern and consider whether another condition may be contributing before you spend money on a procedure. Established hair transplantation redistributes existing follicles; it does not stop the underlying process that may affect untreated hair. Ask for a personalized discussion of alternatives, expected limitations, and how your hair loss may change over time (ISHRS patient guidance).

Do not assume that promising early research means a treatment is ready for routine care. Even when a study reports improvement, its participants, product, and follow-up may differ from what a clinic offers. A careful second opinion can help you compare options without treating travel or a “stem cell” label as evidence of effectiveness.

Frequently Asked Questions

Are stem cell hair treatments abroad FDA-approved?

No stem cell or regenerative product is FDA-approved for hair loss, according to the FDA’s patient information. A treatment offered in another country may be subject to that country’s rules, so ask for the exact authorization and verify it with the relevant regulator rather than relying on a clinic’s wording (FDA patient information).

Do these treatments grow new hair follicles?

Some approaches are being studied, but lab-grown, functional follicles are not clinically available for transplantation. Current FUE and FUT procedures redistribute existing follicles rather than create new ones (ISHRS patient guide). Ask clinics to clarify whether they mean improved growth from existing follicles or actual new follicle formation.

What should I do if a clinic promises guaranteed results?

Treat a guarantee as a reason to pause and request written evidence, clear risks, and an independent medical opinion. Ask for the exact product and protocol, and make sure you have a realistic follow-up plan at home. You can postpone travel while you verify the information.

Before booking stem cell hair treatment abroad, take time to verify the clinician, product, regulatory status, evidence, and follow-up plan. A cautious decision—and a qualified second opinion—can help you protect your health and make an informed choice.

Pattern hair loss can involve a surprising mismatch: hair follicle stem cells may remain in the scalp even as the cells needed to produce robust hair become depleted. This helps explain why follicles gradually shrink rather than simply disappearing at the first sign of thinning. It also points to a possible biological opportunity—but surviving stem cells do not guarantee that a miniaturized follicle can be restored or that a regenerative treatment will work.

What happens during follicle miniaturization?

In androgenetic alopecia (AGA), also called pattern hair loss, affected follicles progressively produce finer, shorter hairs. Over time, a thick, pigmented hair may become a less noticeable, wispy hair. This process is called miniaturization. It can make scalp coverage look reduced even before follicles have completely stopped producing visible hair.

The process is linked to androgen signaling. In susceptible scalp areas, testosterone can be converted into dihydrotestosterone (DHT) by the enzyme 5-alpha-reductase. DHT acts on androgen receptors in the follicle environment, and increased 5-alpha-reductase activity and androgen receptor presence are associated with balding scalp. The type 2 form of the enzyme is considered especially relevant in AGA (StatPearls’ overview of androgenetic alopecia).

The result is not simply “too few stem cells.” Instead, androgen signaling can disrupt communication between the dermal papilla—the signaling structure at the base of the follicle—and other follicle cells. This can interfere with pathways that help initiate and maintain hair growth, including canonical Wnt-beta-catenin signaling (a review by Tosti and colleagues).

Hair follicle stem cells can survive while progenitors decline

Hair follicle stem cells (HFSCs) are long-lived cells that help maintain and regenerate the follicle. They are not the same as the more active progenitor cells that multiply and contribute to producing a growing hair. In pattern hair loss, research describes a reduction in progenitor cells while HFSCs remain present. In other words, the follicle’s reserve may persist even when the steps that turn that reserve into productive growth are impaired (Tosti and colleagues’ review of hair loss and stem-cell approaches).

Dermal papilla cells also matter. These cells help signal hair growth and influence the hair cycle; they have characteristics similar to mesenchymal stem cells. When androgen-related signaling changes the dermal papilla’s activity, the presence of HFSCs alone may not be enough to produce a thick hair. This distinction helps explain why “the stem cells are still there” is not the same as saying a follicle is ready to regrow normally.

Is miniaturization reversible?

“Reversible” can mean different things. A follicle that still makes a fine hair may have more potential to improve than one that has been inactive for a long time, but the survival of HFSCs is not a clinical test that predicts an individual outcome. The relevant challenge is restoring the coordinated signals and cell activity needed for a stronger hair—not merely adding stem cells.

Some investigational approaches aim to influence this environment through transplanted cells or micrografts, stem-cell-conditioned medium, or cell-derived exosomes. However, these approaches differ in what they contain and how they are prepared. Reviews of human studies describe promising signals but also limitations, including small samples, varied protocols, and short follow-up (the 2023 systematic review in Cells).

At present, no stem-cell or regenerative product is FDA-approved for hair loss. A treatment marketed as “stem cell therapy” is not necessarily a procedure that creates new follicles, and there is no established clinical procedure that grows new follicles in a laboratory and transplants them. Hair transplant surgery, by contrast, redistributes a patient’s existing follicles from one scalp area to another (FDA patient information on regenerative medicine; ISHRS patient guide).

What to ask before considering a regenerative treatment

Marketing language can make different procedures sound interchangeable. Ask what material is used, how it is prepared, what the treatment is intended to do, and what human evidence supports that specific protocol. Request a clear discussion of uncertainty, potential risks, costs, and alternatives. If a clinic claims it can create new follicles or permanently reverse miniaturization, ask for evidence that directly supports that claim rather than relying on general statements about stem cells.

A consultation should also consider whether the hair loss is actually pattern hair loss. Other conditions can cause shedding or thinning, and an accurate diagnosis helps guide appropriate next steps. Many Hair Transplant Clinics offer consultations about surgical and nonsurgical options, but a consultation is not proof that a regenerative product is established or suitable for you. When you visit a Hair Transplant Clinic, ask how the provider distinguishes existing miniaturized follicles from areas where follicles are no longer producing visible hair.

Frequently Asked Questions

Do hair follicle stem cells disappear in pattern hair loss?

Not necessarily. Research describes HFSCs persisting while hair progenitor cells become depleted, so the problem can involve impaired activity and signaling rather than the complete loss of the stem-cell reserve (Tosti and colleagues’ review). This finding does not predict whether a particular person’s hair will regrow.

Does finding surviving stem cells mean hair loss can be reversed?

No. Surviving cells may provide a biological basis for research, but follicle function depends on multiple cell types and signals. A clinician can assess the pattern and possible options, but no one can guarantee that miniaturized follicles will return to their previous thickness.

Are stem-cell treatments proven to regrow hair?

Human research is ongoing, but the approaches and study methods vary, and results should not be treated as a guarantee for an individual. No stem-cell or regenerative product is FDA-approved for hair loss, so ask providers to explain the evidence and regulatory status of the exact treatment they offer (FDA patient information).

Understanding the difference between surviving stem cells and functioning hair-producing cells makes pattern hair loss easier to discuss—and helps separate plausible science from promises. If you are concerned about thinning, seek an assessment and ask for a clear explanation of the diagnosis, evidence, and realistic options.

Autologous micrografts are small, cell-containing materials taken from a patient and studied as a possible way to support hair growth. Early research is encouraging but limited: studies use different cell sources and methods, and there is not yet enough consistent evidence to know which approach works best, for whom, or how long results may last.

What “autologous micrograft” means

“Autologous” means that the material comes from the same person who receives it. In hair research, micrografts may contain cells from hair follicles, while other investigational approaches use cells or cell-derived materials from sources such as adipose tissue or bone marrow. The exact tissue source, preparation, and treatment method can vary, so the word “micrograft” alone does not tell you what a provider is offering. Researchers are studying several distinct approaches, including cell transplantation, conditioned media, and exosomes (a review of stem-cell approaches to hair loss).

These treatments should not be confused with conventional hair transplantation. FUE and FUT move a patient’s existing follicles from one area of the scalp to another; they do not create new follicles. Lab-grown follicles that could be transplanted and function normally are not clinically available (the ISHRS patient guide and a review of follicle regeneration).

What a micrograft trial may involve

A clinical trial is designed to evaluate a specific intervention using a defined protocol. For an autologous treatment, the material is sourced from the participant, but details such as the tissue source, how it is prepared, how it is delivered, and whether it is compared with another treatment depend on that particular study. Do not assume that two treatments described as “micrografts” are equivalent; ask for the study protocol or a plain-language explanation of what differs.

Before considering participation, ask who is responsible for the procedure and follow-up, what outcomes the researchers will measure, how long participants will be monitored, and what risks or costs apply. A trial’s consent materials should explain that the treatment is investigational and clarify what is known and unknown. When you visit a Hair Transplant Clinic, ask whether the offering is part of a registered clinical study or a commercial service, and request the evidence for the exact product and protocol being proposed. Many Hair Transplant Clinics discuss regenerative options, but a label or marketing description is not proof of established benefit.

What the research can—and cannot—tell us

A 2023 systematic review included 15 studies and 653 participants using several different cell-based approaches, including hair-follicle stem cells and micrografts. The studies generally reported increased hair density, but the review noted small samples, varied protocols, and short follow-up—limitations that make it difficult to draw firm conclusions about effectiveness or durability (the systematic review in Cells). Because the review grouped distinct treatments, its overall findings should not be interpreted as proof that every micrograft product works.

A 2026 systematic review covered 20 clinical studies and 724 patients across multiple regenerative approaches (systematic review in Stem Cell Research & Therapy). Only three studies, involving 146 patients, examined stem cells or micrografts; the rest studied other approaches such as conditioned media, platelet-rich fibrin, or extracellular vesicles. This broader evidence base provides context, but results from one category cannot be assumed to apply to another (the systematic review in Stem Cell Research & Therapy).

The biological rationale is under study: pattern hair loss involves changes in follicle signaling, and researchers are investigating whether cell-based treatments can influence that environment. A plausible mechanism, however, is not the same as demonstrated clinical benefit. Larger, well-designed studies with consistent methods and longer follow-up are needed to establish which patients may benefit and whether any improvement lasts (a review of stem-cell biology in hair loss).

Safety, regulation, and questions to ask

“Autologous” does not mean risk-free or proven. The FDA states that regenerative medicine products are not approved for hair loss; patients should be cautious about claims that an investigational treatment is established or guaranteed (FDA information for patients). Exosomes are a separate category from micrografts, and they also have no FDA approval for hair loss; the American Hair Loss Association notes that human evidence remains preliminary and protocols are not standardized (exosome status information).

Before agreeing to treatment, ask what material is used, whether it comes from your own tissue, how it is processed, and what published human research studied that exact method. Ask for realistic expectations, potential risks, total cost, and whether standard hair-loss diagnosis or treatments should also be discussed. Clear answers should distinguish established care from research-stage options rather than relying on broad phrases such as “stem-cell restoration.”

Frequently Asked Questions

Are autologous micrografts the same as a hair transplant?

No. A conventional transplant redistributes existing follicles, while micrograft approaches are being studied as cell-based treatments. The terms describe different approaches, and the exact method should be confirmed with the provider (ISHRS patient guide).

Do micrografts have proven, lasting results?

Current reviews include small studies with different treatment methods and limited follow-up, so they do not establish a reliable long-term result for every micrograft approach. Ask whether evidence relates to the exact protocol being offered, rather than to regenerative treatments as a broad category (2023 systematic review).

Does using my own cells mean the treatment is approved?

No. Using a patient’s own tissue does not by itself establish safety, effectiveness, or regulatory approval. The FDA advises patients to verify the status of regenerative products and discuss claims with a qualified medical professional (FDA patient information).

Micrografts are an active area of research, but the evidence is still developing and products with similar names may differ substantially. Take time to understand the specific protocol, its evidence, and its uncertainties before deciding whether to participate in a trial or pursue a commercial treatment.

Hair follicle neogenesis means creating entirely new follicles, rather than restoring or relocating ones that already exist. Researchers are investigating ways to encourage follicle growth, but new lab-grown follicles are not currently available as a clinical treatment. Hair transplant surgery moves a patient’s existing follicles from one area of the scalp to another; it does not create new ones (ISHRS patient guide).

Neogenesis is different from regeneration

The terms neogenesis and regeneration are sometimes used interchangeably in promotional material, but they describe different goals. Neogenesis refers to forming a follicle anew. Regeneration is a broader term that can mean improving the activity of an existing follicle or supporting the hair-growth environment. A treatment that increases hair density or thickness does not, by itself, prove that new follicles have formed.

That distinction matters in pattern hair loss. Follicles can gradually miniaturize, producing finer, shorter hairs. Research reviews describe changes in follicle signaling in androgenetic alopecia, including effects involving dermal papilla cells and Wnt-beta-catenin signaling (review by Tosti and colleagues). Supporting a miniaturized follicle and building a completely new, functional follicle are not the same biological task.

Why dermal papilla cells matter

A hair follicle is not just a strand-producing opening in the skin. It is a small, organized structure whose cells communicate with one another through growth signals. Dermal papilla (DP) cells sit at the base of the follicle and help direct hair growth and regulate the hair cycle. They have stem-cell-like characteristics, but that does not mean that a DP-cell injection automatically creates a new follicle.

Hair follicle stem cells (HFSCs) and hair progenitor cells also have different roles. In pattern hair loss, HFSCs may remain present while progenitor-cell activity is reduced; altered androgen signaling can affect DP-cell signals and inhibit canonical Wnt-beta-catenin activity (Tosti and colleagues’ review). This helps explain why researchers study cell signals and supporting cells—but translating those findings into reliable, newly formed follicles remains a separate challenge.

What wound-induced research is exploring

Wound-induced follicle neogenesis is a research idea about whether signals associated with skin injury and healing might prompt new follicles to form. It is not an established way to regrow hair in patients. Reviews of follicle regeneration describe the broader scientific challenge: a lab-grown follicle would need to develop into a functional structure, cycle through growth phases, connect with surrounding tissue, receive a blood supply, and produce appropriately pigmented hair (follicle regeneration review).

Those requirements help explain why “hair cloning” or “new follicle creation” claims should be assessed carefully. A promising cell signal, an increase in visible hair, and a fully formed follicle that can keep cycling are different outcomes. At present, there is no established surgical procedure that creates new lab-grown follicles and transplants them (FDA information on regenerative medicine).

What current regenerative treatments can and cannot show

Investigational approaches include cell transplantation or micrografts, conditioned media, and exosomes. A 2023 systematic review summarized 15 studies involving 653 participants and several different cell-based methods. The studies reported increased hair density, but the authors noted limitations including small samples, varied protocols, and short follow-up (systematic review in Cells). These findings are preliminary; they do not establish that the treatments create new follicles.

Platelet-rich plasma (PRP) is another treatment sometimes discussed alongside regenerative procedures, but it is not the same as follicle neogenesis. In a 2020 systematic review of 12 PRP studies in androgenetic alopecia, 10 reported a positive effect, while six reported statistically significant improvement in objective measures; two found no significant improvement. The review also noted mild side effects such as temporary pain or itching (PRP systematic review). Results from these studies should not be treated as a guarantee for an individual patient.

No stem-cell or regenerative product is FDA-approved for hair loss, and evidence and protocols vary. Exosomes in particular are not FDA-approved for hair loss or any other condition, and available human evidence remains preliminary (American Hair Loss Association information on exosomes). When you speak with a Hair Transplant Clinic, ask whether a proposed treatment aims to support existing follicles or claims to create new ones, what evidence supports that specific method, and what uncertainties remain. Hair Transplant Clinics may use similar-sounding terms for different procedures, so ask the provider to explain exactly what is done and what outcome is being measured.

Frequently Asked Questions

Can a hair transplant create new follicles?

No. FUE and FUT surgery relocate a patient’s existing follicles; they do not generate new ones (ISHRS patient guide). A transplant may redistribute hair to improve coverage, but it cannot increase the total number of follicles available from the donor area.

Are stem-cell hair treatments proven to grow new follicles?

No established treatment has been shown to create transplantable, lab-grown follicles in routine clinical care. Studies of cell-based approaches are investigating possible effects on hair growth, but varied methods and limited follow-up make it important to distinguish early findings from proven neogenesis (systematic review in Cells).

What should I ask about a “new follicle” claim?

Ask what the treatment physically involves, whether the goal is to support existing follicles or form new ones, and what published human evidence supports the claim. You can also ask about regulatory status and risks; FDA registration of a facility or an investigational application should not be confused with FDA approval (FDA patient information).

For now, follicle neogenesis remains a research goal rather than an available hair-restoration procedure. Understanding the difference between new follicle formation and support for existing follicles can help you evaluate claims and have a clearer discussion with a qualified clinician.